12:32 PM EST, 12/08/2025 (MT Newswires) -- (Updates with recent stock price movement in the headline and first paragraph.)

Wave Life Sciences ( WVE ) shares were up more than 125% in recent Monday trading after the company said interim data from its phase 1 trial of WVE-007 to treat obesity showed improvements in body composition, with weight loss similar to GLP-1, but without muscle loss, at three months compared to baseline at its lowest therapeutic dose.

The study demonstrated a single 240 mg dose of WVE-007 led a 9.4% reduction in visceral fat, a 4.5% reduction in total body fat, and a 3.2% increase in lean mass, the biotechnology company said. Interim data further showed WVE-007 was generally safe and well tolerated with only mild treatment related adverse events, Wave Life Sciences ( WVE ) said.

The company said further clinical data updates were expected in Q1 of 2026, which include a six-month follow-up from the 240 mg single-dose group.

Price: 16.88, Change: +9.39, Percent Change: +125.37